Cipaglucosidase alfa Side Effects
Medically reviewed by Drugs.com. Last updated on Jan 17, 2024.
Applies to cipaglucosidase alfa: intravenous powder for solution.
Warning
Intravenous route (Powder for Solution)
Severe Hypersensitivity Reactions, Infusion-Associated Reactions, and Risk of Acute Cardiorespiratory Failure in Susceptible PatientsHypersensitivity Reactions Including AnaphylaxisPatients treated with cipaglucosidase alfa-atga have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available during cipaglucosidase alfa-atga administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, cipaglucosidase alfa-atga should be discontinued immediately, and appropriate medical treatment should be initiated. In patients with severe hypersensitivity reaction, desensitization measures to cipaglucosidase alfa-atga may be considered.Infusion-Associated Reactions (IARs)Patients treated with cipaglucosidase alfa-atga have experienced severe IARs. If severe IARs occur, immediately discontinue the cipaglucosidase alfa-atga infusion, initiate appropriate medical treatment, and assess the benefits and risks of readministering cipaglucosidase alfa-atga following severe IARs. Patients with an acute underlying illness at the time of cipaglucosidase alfa-atga infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs.Risk of Acute Cardiorespiratory Failure in Susceptible PatientsPatients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during cipaglucosidase alfa-atga infusion. More frequent monitoring of vitals should be performed during cipaglucosidase alfa-atga infusion in such patients.
Serious side effects
Along with its needed effects, cipaglucosidase alfa may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking cipaglucosidase alfa:
Less common
- Blurred vision
- chest tightness
- chills
- confusion
- cough
- difficulty swallowing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fast, pounding, or irregular heartbeat or pulse
- feeling of warmth
- fever
- headache
- hives, itching, skin rash
- increased blood pressure
- lower back or side pain
- nausea and vomiting
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the face, neck, arms and occasionally, upper chest
- shakiness in the legs, arms, hands, or feet
- sweating
- trembling or shaking of the hands or feet
- trouble breathing
- unusual tiredness or weakness
Other side effects
Some side effects of cipaglucosidase alfa may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Less common
- Acid or sour stomach
- belching
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- change in taste
- constipation
- difficulty in moving
- full or bloated feeling
- general feeling of discomfort or illness
- heartburn
- indigestion
- joint or muscle pain
- lack or loss of strength
- loss of taste
- muscle spasms
- pressure in the stomach
- stomach discomfort, upset, or pain
- swelling of the stomach area
For Healthcare Professionals
Applies to cipaglucosidase alfa: intravenous powder for injection.
General
The most common adverse reactions occurring in 5% of patients or greater who were treated with this drug in combination with miglustat were headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia.
The most common adverse reactions attributable only to cipaglucosidase alfa were chills, dizziness, flushing, somnolence, chest discomfort, cough, infusion site swelling, and pain.[Ref]
Cardiovascular
Common (1% to 10%): Flushing, increased blood pressure/hypertension, tachycardia including sinus tachycardia
Uncommon (0.1% to 1%): Hypotension, pallor
Dermatologic
Common (1% to 10%): Rash, pruritus, urticaria, hyperhidrosis
Uncommon (0.1% to 1%): Skin abrasion, skin discoloration, skin edema
Rash included erythematous rash and macular rash.
Urticaria included mechanical urticaria and urticarial rash.
Gastrointestinal
Common (1% to 10%): Abdominal distension, diarrhea, upper and lower abdominal pain, nausea, dysgeusia, dyspepsia, constipation, flatulence, vomiting
Uncommon (0.1% to 1%): Esophageal pain, esophageal spasm, oral discomfort, oral pain, swollen tongue
Hematologic
Common (1% to 10%): Decreased platelet count
Uncommon (0.1% to 1%): Decreased lymphocyte count
Hypersensitivity
Very common (10% or more): Hypersensitivity reactions (up to 27%)
Anaphylaxis signs and symptoms included dyspnea, rash, hypotension, bronchospasm, edema, pharyngeal edema, and tongue swelling.
Severe hypersensitivity reaction symptoms included urticaria, pruritus, and flushing.
Immunologic
Very common (10% or more): Anti-drug antibodies (up to 89%), enzyme inhibiting antibodies (up to 82%), infusion-associated reactions (up to 32%)
Local
Common (1% to 10%): Infusion site swelling, infusion site pain
Musculoskeletal
Common (1% to 10%): Muscle spasm, flank pain, myalgia, arthralgia, muscular weakness
Uncommon (0.1% to 1%): Muscle fatigue, musculoskeletal stiffness
Nervous system
Common (1% to 10%): Headache, dizziness, paresthesia, tremor, somnolence
Uncommon (0.1% to 1%): Balance disorder, burning sensation, presyncope
Headache included migraine and migraine with aura.
Other
Common (1% to 10%): Pyrexia, chills, malaise, pain, asthenia, fatigue, chest discomfort
Uncommon (0.1% to 1%): Body temperature fluctuations, non-cardiac chest pain, peripheral swelling, facial pain
Respiratory
Common (1% to 10%): Dyspnea, cough
Uncommon (0.1% to 1%): Asthma, oropharyngeal discomfort, pharyngeal edema, wheezing
More about cipaglucosidase alfa
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: lysosomal enzymes
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. (2023) "Product Information. Pombiliti (cipaglucosidase alfa)." Amicus Therapeutics U.S., Inc.
2. (2023) "Product Information. Pombiliti (cipaglucosidase alfa)." Amicus Therapeutics UK Operations Ltd
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.